News
ABEO
5.40
-0.55%
-0.03
Abeona, NexGen, Nano Nuclear, SanDisk, Tempus Trending
TipRanks · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Abeona Therapeutics (ABEO), M3 (MTHRF)
TipRanks · 2d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 5d ago
Weekly Report: what happened at ABEO last week (0914-0918)?
Weekly Report · 6d ago
Rocket, Copart, Pegasystems, Abeona, Fluence trending by analysts
TipRanks · 09/19 09:01
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga · 09/18 12:31
Abeona Therapeutics (ABEO) Highlights FDA Approval Of FAYUVI Gene Therapy For MPS IIIA
NASDAQ · 09/18 12:01
Analysts Offer Insights on Healthcare Companies: Heart Test Laboratories, Inc. (HSCS), Ultragenyx Pharmaceutical (RARE) and Abeona Therapeutics (ABEO)
TipRanks · 09/18 12:00
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
Benzinga · 09/18 11:51
Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111
TipRanks · 09/18 11:35
Abeona Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 09/18 09:55
Abeona Therapeutics Price Target Raised to $30.00/Share From $28.00 by Cantor Fitzgerald
Dow Jones · 09/18 09:55
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30
Benzinga · 09/18 09:45
Abeona Therapeutics Price Target Announced at $17.00/Share by Roth Capital
Dow Jones · 09/17 10:20
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17
Benzinga · 09/17 10:09
Abeona Therapeutics initiated with a Buy at Roth Capital
TipRanks · 09/17 08:35
Abeona Activates Eighth U.S. Testing Site For ZEVASKYN In Epidermolysis Bullosa; Stock Down
NASDAQ · 09/16 19:11
Abeona activates UF Health as qualified treatment center for Zevaskyn
TipRanks · 09/16 11:35
Abeona Therapeutics Updates Investor Presentation at Conference
TipRanks · 09/15 16:47
Weekly Report: what happened at ABEO last week (0907-0911)?
Weekly Report · 09/14 09:18
More
Webull provides a variety of real-time ABEO stock news. You can receive the latest news about Abeona Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).